PFAS Exposure tied with Weaker Bones in Teen Boys: Study
PFAS Exposure is tied with Weaker Bones in Teen Boys, according to a recent study published in The Journal of Clinical Endocrinology & Metabolism.
Per- and polyfluoroalkyl substances (PFAS) and phthalates are two families of environmental endocrine disruptors that may be associated with areal lower bone mineral density (aBMD).
A study examined associations between serum PFAS and urinary phthalate biomarker concentrations and their mixtures with aBMD Z-score in adolescents.
They examined serial cross-sectional data from male (n=453) and female (n=395) 12-19 year old participants in the 2011—2016 National Health and Nutrition Examination Survey with measures of serum PFAS, urinary phthalate metabolites, and dual-energy X-ray absorptiometry aBMD Z-score (total body less head). In sex-specific models, we used linear regression to examine associations of individual PFAS and phthalate biomarkers with aBMD Z-score, and Bayesian kernel machine regression (BKMR) to examine the association of the overall PFAS/phthalate biomarker mixture with aBMD Z-score. We replicated the analysis, stratifying by race/ethnicity.
Results:
- Participants were (mean ± SD) 15 ± 2.1 years old.
- In males, each doubling of serum perfluorooctanoate (PFOA), perfluorooctane sulfonate rinary mono-isobutyl phthalate (MiBP), mono-n-butyl phthalate, and the overall PFAS/phthalate mixture was associated with a lower aBMD Z-score (e.g., for PFOA: -0.24, 95% CI, -0.41, -0.06).
- Serum PFOA and urinary MiBP were associated with higher aBMD Z-score in females (e.g., for PFOA: 0.09, 95% CI, -0.07, 0.25). Findings did not differ by race/ethnicity.
Thus, certain PFAS and phthalates may reduce bone mineral density in adolescent males. Bone mineral density tracks across the lifecourse, so if replicated in longitudinal cohorts, this finding may have implications for lifelong skeletal health.
Reference:
Serum PFAS and Urinary Phthalate Biomarker Concentrations and Bone Mineral Density in 12-19 Year Olds: 2011-2016 NHANES Get access Arrow by Jenny L Carwile et al. published in the Journal of Clinical Endocrinology & Metabolism
https://doi.org/10.1210/clinem/dgac228
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.